Table 1.
Baseline Characteristics of the Enrolled Study Population
| PCSK9 Inhibitor Group (n = 30) | Placebo Group (n = 30) | |
|---|---|---|
| Age, y | 66.07 ± 12.09 | 66.23 ± 11.85 |
| Female | 11 (37) | 12 (40) |
| BMI, kg/m2 | 29.94 ± 5.40 | 29.80 ± 5.21 |
| Cardiovascular disease | 6 (20) | 8 (27) |
| Diabetes | 8 (27) | 9 (30) |
| COPD | 3 (10) | 2 (7) |
| Chronic kidney disease | 1 (3) | 2 (7) |
| LDL-C, mg/dL | 78.43 ± 26.10 | 77.23 ± 30.9 |
| Acetylsalicylic acid | 8 (27) | 8 (27) |
| P2Y12 inhibitor | 1 (3) | 0 (0) |
| Angiotensin-converting enzyme inhibitor | 10 (33) | 12 (40) |
| Beta-blockers | 15 (50) | 13 (43) |
| Statins | 11 (36.7) | 10 (33.3) |
| Days from illness onset to randomization | 7.80 ± 2.55 | 8.80 ± 4.17 |
| Vaccinated | 30 (100) | 30 (100) |
| Oxygenation index | 101.22 (83.52-157.82) | 107.75 (75.52-160.31) |
| Unfractionated heparin | 30 (100) | 28 (93) |
| Systolic blood pressure, mm Hg | 128.88 ± 16.90 | 123.55 ± 17.95 |
| Diastolic blood pressure, mm Hg | 71.07 ± 9.85 | 72.13 ± 13.73 |
| Remdesivir | 8 (27) | 10 (33) |
| Steroids | 25 (83) | 26 (87) |
| Antibiotics | 27 (90) | 28 (93.3) |
| Leukocytes (×103/μL) | 6.6 (5.29-9.41) | 7.85 (5.86-10.7) |
| Neutrophils (×103/μL) | 5.01 (4.21-7.73) | 6.85 (4.7-8.46) |
| Platelets (×103/μL) | 248.07 ± 104.23 | 258.93 ± 89.27 |
| Hemoglobin, g/dL | 12.59 ± 1.43 | 12.96 ± 1.94 |
| CRP, mg/dL | 129.21 (93.5-180.8) | 132.29 (59.38-182.0) |
| D-dimer, ng/mL | 1093.47 (643.01-1,675.25) | 1233 (910-2,429.25) |
| Fibrinogen, mg/dL | 541 (484-709) | 606 (508-761) |
Values are mean ± SD, n (%), or median (IQR).
BMI = body mass index; COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; LDL = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9.